Ix Biopharma Ltd. announced the appointment of Lam Li Fong as general manager, effective September 25, 2015. He is responsible for the overall management and operations of Syrinx Pharmaceuticals which operates the company's manufacturing facility. Previously he worked as chief executive officer of Oversee Arrow Laboratories operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.032 SGD | -3.03% | -5.88% | -28.89% |
Jun. 19 | Ix Biopharma Cuts Conversion Price of 9% Convertible Bonds | MT |
Jun. 11 | Singapore Shares Fall As Federal Interest Rate Cut Hopes Dim; China Mining Up 29% | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.89% | 18.73M | |
+51.26% | 798B | |
+41.54% | 633B | |
-5.18% | 356B | |
+19.57% | 328B | |
+10.56% | 304B | |
+17.85% | 244B | |
+3.68% | 227B | |
+11.26% | 216B | |
+7.98% | 166B |
- Stock Market
- Equities
- 42C Stock
- News iX Biopharma Ltd.
- Ix Biopharma Ltd. Announces Appointment of Lam Li Fong as General Manager